Trial Profile
A Phase 1 Study to Investigate Absorption, Metabolism, and Excretion After Establishment of Steady State Via GBT440 Loading and Maintenance Dosing Followed by a Single Oral Dose Administration of [14C]-GBT440 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2017
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Global Blood Therapeutics
- 06 Dec 2016 Status changed from active, no longer recruiting to completed, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results assessing safety and pharmacokinetics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 04 Dec 2016 According to a Global Blood Therapeutics media release, data from this trial were presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition